Welcome to Lab Dish, a brand new First Opinion column on regenerative medication from Paul Knoepfler.
There are particular leaders who quietly make advanced organizations function properly together with within the hardest of occasions—leaders like Peter Marks, director of the Middle for Biologics Analysis and Analysis (CBER), who resigned Friday. Marks’ effectiveness on the Meals and Drug Administration saved numerous lives and tremendously superior the cell and gene remedy subject.
Marks, whose function additionally made him the FDA’s prime vaccine regulator, was given the selection of resigning or being fired. Now, you will need to mirror on a few of Marks’ accomplishments, what his absence will imply, and the ominous implications of his departure.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
